<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6634">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02027103</url>
  </required_header>
  <id_info>
    <org_study_id>90-111-60037</org_study_id>
    <nct_id>NCT02027103</nct_id>
  </id_info>
  <brief_title>Metformin and Pioglitazone Effects on Fetuin-A and Osteoprotegrin Concentrations in Type 2 Diabetes Patients</brief_title>
  <official_title>Comparative Effects of Metformin and Pioglitazone on Fetuin-A and Osteoprotegerin Concentrations in Patients With Newly Diagnosed Diabetes: A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tehran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tehran University of Medical Sciences</source>
  <oversight_info>
    <authority>Iran: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oral hypoglycemic agents, along with dietary modification and exercise encompass the
      mainstay of treatment in early stages of T2DM. Biguanides and thiazolidinediones are two
      major groups of hypoglycemic medications that while function via different pathways, mare
      both effective in short- and long-term glucose control. These medications diminish or delay
      long term micro- and macrovascular complications associated with T2DM although at different
      rates. Excessive insulin resistance accounts for a sustained increase in cardiovascular
      incidents in T2DM subjects. Given the shared pathway of insulin resistance/fetuin-A/OPG in
      atherosclerosis formation, it is conceivable that insulin sensitizing anti-diabetes
      medications are able to modify successive CAD risk via direct and indirect amelioration of
      insulin resistance/fetuin-A/OPG. The present study is therefore designed to investigate the
      effects of metformin and pioglitazone monotherapy on serum concentrations of fetuin-A and
      OPG in a group of Iranian adults with newly diagnosed T2DM.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Serum concentrations of fetuin-A</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum concentrations of osteoprotegrin</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients receiving fixed dose metformin 1000 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pioglitazone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients receiving fixed dose pioglitazone 30 mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin 1000 mg fixed dose, twice daily (500 mg tablets x 2)</description>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>Pioglitazone 30 mg fixed dose, twice daily (15 mg tablets x 2)</description>
    <arm_group_label>Pioglitazone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Newly diagnosed type 2 diabetes patients based on American Diabetes Association criteria
        (2011) for diagnosis of diabetes

        Exclusion Criteria:

        Previous intake of oral hypoglycemic agents for treatment of diabetes or other
        hyperglycemia associated conditions Intake of glucocorticoids in the past one year Major
        illnesses of heart, lung, kidney, and liver.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alireza Esteghamati, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tehran University of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Diabetes Clinic, Vali-Asr Hospital, Tehran University of Medical Sciences</name>
      <address>
        <city>Tehran</city>
        <zip>13145-784</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 2, 2014</lastchanged_date>
  <firstreceived_date>January 2, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tehran University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Alireza Esteghamati</investigator_full_name>
    <investigator_title>Alireza Esteghamati, M.D.</investigator_title>
  </responsible_party>
  <keyword>Fetuin-A</keyword>
  <keyword>OPG</keyword>
  <keyword>Metformin</keyword>
  <keyword>Pioglitazone</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
